# Efficacy and Safety of Midodrine in Refractory or Recurrent Ascites in Children With Cirrhosis.

> **NCT05084534** · NA · WITHDRAWN · sponsor: **Institute of Liver and Biliary Sciences, India**

## Conditions studied

- Refractory Ascites in Children With Cirrhosis

## Interventions

- **DRUG:** Midodrine
- **OTHER:** Standard medical treatment

## Key facts

- **NCT ID:** NCT05084534
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11-01
- **Primary completion:** 2023-02
- **Final completion:** 2023-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No cases of refractory ascites presented to hospital in one year
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084534, "Efficacy and Safety of Midodrine in Refractory or Recurrent Ascites in Children With Cirrhosis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05084534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*